- Previous Close
3,161.35 - Open
3,160.20 - Bid 3,255.90 x --
- Ask 3,262.00 x --
- Day's Range
3,150.00 - 3,272.00 - 52 Week Range
2,488.00 - 3,589.95 - Volume
5,275 - Avg. Volume
4,775 - Market Cap (intraday)
1.103T - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
59.18 - EPS (TTM)
55.08 - Earnings Date Jan 24, 2025
- Forward Dividend & Yield 28.00 (0.86%)
- Ex-Dividend Date Jun 21, 2024
- 1y Target Est
3,639.83
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
www.torrentpharma.com15,718
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TORNTPHARM.BO
View MorePerformance Overview: TORNTPHARM.BO
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TORNTPHARM.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TORNTPHARM.BO
View MoreValuation Measures
Market Cap
1.10T
Enterprise Value
1.12T
Trailing P/E
59.23
Forward P/E
56.50
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.93
Price/Book (mrq)
14.70
Enterprise Value/Revenue
10.08
Enterprise Value/EBITDA
30.27
Financial Highlights
Profitability and Income Statement
Profit Margin
16.06%
Return on Assets (ttm)
11.71%
Return on Equity (ttm)
25.37%
Revenue (ttm)
112.24B
Net Income Avi to Common (ttm)
18.02B
Diluted EPS (ttm)
55.08
Balance Sheet and Cash Flow
Total Cash (mrq)
12.35B
Total Debt/Equity (mrq)
41.66%
Levered Free Cash Flow (ttm)
23.58B